BioDelivery Sciences International, Inc. Expected to Post Q1 2017 Earnings of $0.09 Per Share (BDSI)

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) – Equities research analysts at Roth Capital issued their Q1 2017 EPS estimates for BioDelivery Sciences International in a report issued on Tuesday, Zacks Investment Research reports. Roth Capital analyst S. Henry forecasts that the specialty pharmaceutical company will post earnings of $0.09 per share for the quarter. Roth Capital has a “Buy” rating and a $5.00 price objective on the stock. Roth Capital also issued estimates for BioDelivery Sciences International’s Q2 2017 earnings at ($0.24) EPS, Q3 2017 earnings at ($0.23) EPS, Q4 2017 earnings at ($0.21) EPS, FY2017 earnings at ($0.59) EPS and FY2018 earnings at ($0.55) EPS.

BDSI has been the subject of several other reports. Zacks Investment Research raised shares of BioDelivery Sciences International from a “sell” rating to a “buy” rating and set a $2.00 price target for the company in a research note on Tuesday, January 10th. Cantor Fitzgerald set a $3.00 price target on shares of BioDelivery Sciences International and gave the stock a “hold” rating in a research note on Tuesday, January 17th. FBR & Co set a $5.00 price objective on shares of BioDelivery Sciences International and gave the company a “buy” rating in a research note on Thursday, February 2nd. Finally, Janney Montgomery Scott reaffirmed a “buy” rating and set a $3.00 price objective on shares of BioDelivery Sciences International in a research note on Monday, March 20th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. BioDelivery Sciences International has a consensus rating of “Hold” and a consensus target price of $3.50.

Earnings History and Estimates for BioDelivery Sciences International (NASDAQ:BDSI)

TRADEMARK VIOLATION NOTICE: This report was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright and trademark law. The original version of this report can be read at https://www.com-unik.info/2017/04/21/brokers-set-expectations-for-biodelivery-sciences-international-inc-s-q1-2017-earnings-bdsi-updated-updated.html.

Shares of BioDelivery Sciences International (NASDAQ:BDSI) traded down 3.03% during midday trading on Thursday, reaching $1.60. The company had a trading volume of 281,232 shares. The company has a 50 day moving average price of $1.87 and a 200-day moving average price of $1.96. BioDelivery Sciences International has a one year low of $1.50 and a one year high of $3.78. The firm’s market capitalization is $87.67 million.

BioDelivery Sciences International (NASDAQ:BDSI) last issued its quarterly earnings results on Friday, March 17th. The specialty pharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.26) by $0.03. The company had revenue of $3.90 million for the quarter, compared to analyst estimates of $6.37 million. BioDelivery Sciences International had a negative return on equity of 309.49% and a negative net margin of 93.61%. The company’s quarterly revenue was down 87.9% compared to the same quarter last year. During the same period in the prior year, the company earned $0.19 EPS.

Institutional investors have recently made changes to their positions in the stock. Acadian Asset Management LLC bought a new position in shares of BioDelivery Sciences International during the third quarter valued at about $217,000. GSA Capital Partners LLP bought a new position in shares of BioDelivery Sciences International during the fourth quarter valued at about $142,000. A.R.T. Advisors LLC boosted its position in shares of BioDelivery Sciences International by 174.8% in the fourth quarter. A.R.T. Advisors LLC now owns 98,100 shares of the specialty pharmaceutical company’s stock valued at $171,000 after buying an additional 62,400 shares in the last quarter. Oxford Asset Management boosted its position in shares of BioDelivery Sciences International by 280.8% in the fourth quarter. Oxford Asset Management now owns 107,945 shares of the specialty pharmaceutical company’s stock valued at $189,000 after buying an additional 79,599 shares in the last quarter. Finally, Tiverton Asset Management LLC boosted its position in shares of BioDelivery Sciences International by 206.1% in the third quarter. Tiverton Asset Management LLC now owns 180,417 shares of the specialty pharmaceutical company’s stock valued at $487,000 after buying an additional 121,468 shares in the last quarter. Institutional investors own 53.57% of the company’s stock.

In related news, CEO Mark A. Sirgo sold 110,895 shares of the business’s stock in a transaction dated Friday, March 31st. The shares were sold at an average price of $1.90, for a total transaction of $210,700.50. Following the transaction, the chief executive officer now owns 1,670,157 shares in the company, valued at $3,173,298.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last ninety days, insiders have sold 119,250 shares of company stock valued at $226,644. Insiders own 9.00% of the company’s stock.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

5 Day Chart for NASDAQ:BDSI

Get a free copy of the Zacks research report on BioDelivery Sciences International (BDSI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

What are top analysts saying about BioDelivery Sciences International Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for BioDelivery Sciences International Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit